The number of patients who had no evidence of disease after treatment was nearly twice as high in the group that received chemotherapy with nivolumab, a monoclonal antibody immune checkpoint inhibitor that harnesses the immune system to fight cancer.
“No new agent when added to first-line standard-of-care cisplatin-based chemotherapy has improved overall survival in metastatic urothelial carcinoma until now,” said Matthew Galsky, MD, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, a part of the Tisch Cancer Center at Mount Sinai, and senior author of the publication.
A total of 608 patients participated in this trial. Both overall survival and progression-free survival were higher in patients on the immunotherapy-chemotherapy regimen after almost three years. The median duration of complete response in those patients was 37.1 months compared to 13.2 months for patients on just chemotherapy.
Advertisement
This trial was funded by Bristol Myers Squibb in collaboration with Ono Pharmaceutical Company Ltd. The trial was an international collaboration among several institutions.
Reference :
- Nivolumab/Chemo Yields Survival Benefits in Metastatic Urothelial Carcinoma – (https://www.cancernetwork.com/view/nivolumab-chemo-yields-survival-benefits-in-metastatic-urothelial-carcinoma)
Source: Eurekalert
